JAZZ Stock Recent News

Nineteen abstracts, including eleven late-breaking abstracts, underscore Jazz's leadership and extensive research in sleep medicine, and ongoing commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors only DUBLIN , May 29, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nineteen abstracts, including eleven late-breaking abstracts will be presented at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS) being held June 8-11, 2025, in Seattle. Research to be presented at the meeting include dual late-breaking poster and oral presentations, which highlight the extensive Phase 4 data evaluating the effectiveness of low-sodium oxybate, Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH).

DUBLIN , May 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies Global Healthcare Conference on Thursday, June 5, 2025 Fireside chat at 6:55 a.m. PDT / 9:55 a.m.

Jazz took a step forward with the Chimerix acquisition that should further diversify its revenue base. The oxybate business experienced a setback when Avadel won the appeal that allows Lumryz to compete with Jazz's Xywav in idiopathic hypersomnia. There are three potential catalysts for the oncology business in the second half of the year that should translate to a revenue growth inflection point in 2026.

Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Jeff Macdonald - Executive Director, Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renee Gala - President and Chief Operating Officer Rob Iannone - Executive Vice President, Global Head of R&D and Chief Medical Officer Phil Johnson - Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Jessica Fye - JP Morgan David Amsellem - Piper Sandler Marc Goodman - Leerink Partners. Annabel Samimy - Stifle Joseph Thome - TD Cowen Gregory Renza - RBC Capital Markets Joel Beatty - Baird Ami Fadia - Needham Ashwani Verma - UBS Mohit Bansal - Wells Fargo Gary Nachman - Raymond James Joon Lee - Truist Securities Operator Hello and thank you for standing by.

Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $1.68 per share, missing the Zacks Consensus Estimate of $4.51 per share. This compares to earnings of $2.68 per share a year ago.

– Total revenues of $898 million in 1Q25 –– Xywav ® and Epidiolex ® revenues grew 9% and 10% year-over-year, respectively, in 1Q25 –– Completed submission of sNDA for Zepzelca ® in 1L ES-SCLC –– Affirming 2025 revenue guidance; updating financial guidance to reflect Chimerix acquisition and impact of certain Xyrem® antitrust litigation settlements – DUBLIN , May 6, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2025 and updated financial guidance for 2025. "In the first quarter of 2025, our focus on commercial execution resulted in total revenues of $898 million, led by the strong performance of Xywav and Epidiolex.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.